NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

CompletedN/A

Sponsor: AstraZeneca

Conditions: SARS-CoV-2 Infection

Countries: Japan

To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* For treatment of symptomatic disease caused by SARS-CoV-2 infection; Patients with risk factors for severe SARS-CoV-2 infection who do not require supplemental oxygen.
* For prevention of symptomatic disease caused by SARS-CoV-2 infection; Individuals for whom SARS-CoV-2 vaccination is not recommended OR those who are considered to have an inadequate response to a COVID-19 vaccine due to immunodeficiencies AND who is not close contacts such as family members or other people living in the same dwelling as patients infected with SARS-CoV-2.

Exclusion Criteria:

* None

Locations (18)

Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Fukushima, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Kagoshima, Japan
Kanagawa, Japan
Kyoto, Japan
Mie, Japan
Nara, Japan
Numakunai, Japan
Osaka, Japan
Tokyo, Japan
Tottori, Japan